EUROPEAN CURRICULUM VITAE FORMAT

PERSONAL INFORMATION

Name	GIOVANNI BLANDINO
Home Address	
Office Address	ONCOGENOMIC AND EPIGENETIC UNIT DEPT. OF RESEARCH, ADVANCED DIAGNOSTIC AND TECHNOLOGICAL INNOVATION ITALIAN NATIONAL CANCER INSTITUTE "REGINA ELENA"
Telephone	
Fax	
E-mail	
Nationality	Italian
Date of birth	

EMPLOYMENT HISTORY

• Dates	March 2016-present
• Name and address of employer	Regina Elena National Cancer Institute, Rome Italy
• Occupation or position held	Director of Oncogenomic and Epigenetic Unit
• Dates	January 2016-present
• Name and address of employer	Regina Elena National Cancer Institute, Rome Italy
• Occupation or position held	Director of "Clinical Trials Office" IFO
• Dates	February 2014-2018
• Occupation or position held	Full Professor of Molecular Biology license to Italian Universities
• Dates	March 2013 - present
• Name and address of employer	University of South Africa-UNISA,
• Occupation or position held	Extraordinary Professor, Department of Life Science
• Dates	March 2012 - present
• Name and address of employer	McMaster University, Hamilton Canada
• Occupation or position held	Part Time Associate Professor, Department of Oncology
• Dates	April 2008 - present
• Name and address of employer	Regina Elena National Cancer Institute, Rome Italy
• Occupation or position held	Head of Translational Oncogenomic Laboratory

• Dates	April 2007 – 2011
• Name and address of employer	Regina Elena National Cancer Institute, Rome Italy
• Occupation or position held	Institutional Research Coordinator, Translational Oncogenomics Unit,
• Dates	September 2010
• Name and address of employer	Ludwig Institute for Cancer, University of Oxford, England
• Occupation or position held	Visiting Scientist
• Dates	September 2005
• Name and address of employer	Weizmann Institute of Science, Rehovot Israel
• Occupation or position held	Fellow Scientist at the Department of Molecular Cell Biology
• Dates	January 2002- 2008
• Name and address of employer	Regina Elena National Cancer Institute, Rome Italy
• Occupation or position held	Medical Researcher at the Department of Experimental Oncology
• Dates	June 2001
• Name and address of employer	Mount Sinai Institute, New York, USA
• Occupation or position held	Visiting Scientist at the Department of Nephrology
• Dates	1999-2001
• Name and address of employer	Weizmann Institute of Science, Rehovot, Israel
• Occupation or position held	Telethon Young Fellow, Molecular Oncogenesis Laboratory
• Dates	1995-1999
• Name and address of employer	Weizmann Institute of Science
• Occupation or position held	Postdoctoral Fellow, Department of Molecular Cell Biology
• Dates	1991-1995
• Name and address of employer	Regina Elena National Cancer Institute, Rome Italy
• Occupation or position held	Postdoctoral Fellow (AIRC)
• Dates	1994
• Name and address of employer	National cancer institute of Milan
• Occupation or position held	Specialization in Medical Oncology
• Dates	1990-1991
• Name and address of employer	Institute of Pathology, University of Catania, Italy
• Occupation or position held	Fellow
• Dates	1986-1990
• Name and address of employer	Institute of Pathology, University of Catania, Italy
• Occupation or position held	Research Student

EDUCATION AND TRAINING

• Dates	1994
• Name and type of organisation providing education and training	University of Milan, National Cancer Institute, Milan, Italy

• Title of qualification awarded	Degree
• Level in national classification	Residency Program (Oncology)
• Dates	1990
• Title of qualification awarded	*License to practice Medicine in Italy*
• Dates	1990
• Name and type of organisation providing education and training	University of Catania, Italy
• Title of qualification awarded	Degree
• Level in national classification	M.D.

MOTHER TONGUE	Italian
OTHER LANGUAGES	English
• Reading skills	excellent
• Writing skills	excellent
• Verbal skills	excellent

DRIVING LICENCE Patent B

AWARDS

1991 The Italian Association for Cancer Research (AIRC) Fellowship for postdoctoral research.

1993 The Regina Elena Cancer Institute Fellowship for postdoctoral research.

1995 The Italian Association for Cancer Research (AIRC) International Fellowship for postdoctoral research.

1996 The Feinberg Postdoctoral Fellowship, Weizmann Institute of Science

1999 Young Scientist Fellowship From Telethon.

PROFESSIONAL ORGANIZATIONS (PAST AND PRESENT)

Committee Member: HSFP fellowship and Career Award; ISF-Israel National Foundation; BSF-Binational USA-Israel Foundation; CMRH-Netherland Cancer Research; MRC program; Austrian Cancer Society-Fellowship and Grant Program; Career Program (Associate Professorship) University of Singapore; Dutch Cancer Society; German-Israel Society, North West Cancer Research Fund, AICR, UICC Fellowship Program, Cancer Research UK, AFM-Genethon, Foundation for Polish Science, Bar-Ilan University, Tel-Aviv, Israel, Weizmann Institute of Science, Health Research Board (HRB) Ireland, UK Prostate Cancer, Dept. of Oncology, University of Oxford, Dept. of Oncology, McMaster University, Hamilton, Canada, ERA-NET TRANSCAN, EU-FP7, Health Research Council of New Zeland, Terry Fox Research Institute, Vancouver, Canada (Chair of the Reviewer Panel), Deutsche Forschungsgemeinschaftn German Research Foundation, Wellcome trust/Indian Alliance FellowshipProgram; FNP prize; INSERM grant application.

JOURNAL REVIEWER AND EDITORSHIP

Deputy Editor:Journal of Experimental and Clinical Cancer Research

Editorial Board Member: The Open Cell Signaling Journal; Journal of Experimental and Clinical Cancer Research; The International Journal of Low Radiation; The European Journal of Clinical and Medical Oncology;World Journal of Otorhinolaryngology (WJO);World Journal of Clinical Oncology.

Reviewer for the following journals: Cell, Physiological Reviews, Molecular Cell; The EMBO Journal; Cell Report, Nature Reviews Clinical Oncology; PNAS, Blood; Cancer Discovery; Journal of the National Cancer Institute, PLOS Genetics; Molecular Cell Biology; Cancer Research; EMBO Molecular Medicine; Nature Communications; Oncogene; Nucleic Acid Research, Cell Death and Differentiation; Annals of Oncology; BMC Medicine; Journal of Hepatology; Molecular Oncology;Aging Cell; Molecular Biology of Cell; Genome Biology, Molecular Medicine, Cell Cycle; Leukemia; Clinical Epiegentics; Biochemical Pharmacology; BMC Molecular Biology; Theranostics; Journal of Cell Science, Cellular and Molecular Life Science (CMLS), Proteins, FEBS Letters; RNA Biology; Journal of Molecular Biology; Experimental Cell Research; British Journal of Pharmacology; Int. Journal of Cancer; Scientific Reports; Cancer Letters; Carcinogenesis; Cellular Signaling; Acta Biochimica et Biophysica Sinica; Molecular Carcinogenesis; Archives Journal of Dermatology; European Journal of Cancer; Cell Proliferation, The Open Cell Signaling Journal, Cell Tissue and Research; BBA; Int. J. of Biochem. Cell. Biol; Oncology; Tumor Biology; BMC Genomics; BMC Chemical Biology; Annals of Otology, Rhinology and Laryngology; Breast Cancer Research and Treatment; Cancer Therapeutics; PLoS One, Clinical Epigenetics; Cellular Physiology and Biochemistry, Cell Death and Disease, Molecules, Cancer Biomarkers; Biochemistry and Biophyisics Report; Journal of the American Aging Association; Human Mutation; Cell Communication and Signaling, Drug Design Development and Therapy, Cancer Biomarker, The Journal of Obstetrics and Gynaecology Research, Clinical and Translational Medicine, International Journal of Biological Sciences; Current Pharmaceutical Biotechnology; Experimental Biology and Medicine; International Journal of Brain Disorder and Treatment; Marine Drugs; Journal of CancerResearch and Clinical Oncology; Computers in Biology and Medicine; Journal of Functional Food; Scandinavian Journal of Immunology; Biomedicine and Pharmacotherapy; Expert Opinion on Therapeutic Targets; Rheumathology and Therapy; Epigenomics; Cell Biology and Toxicology; Frontiers in Pharmacology; Frontiers in Molecular and Cellular Oncology; Medical Science Monitor; Molecur Diagnosis and Therapy; Expert Opinion on Drug Delivery; Bioscience Reports; NeuroToxicology.

Member of Quality Assessment Research (VQR) organization of the National University System Evaluation and Research Agency (ANVUR)

ACADEMIC TEACHING

1) Member of Cancer Panel, Juravinski Cancer Centre, McMaster University, Hamilton, Canada.

2) PhD Committee Member, University of Alberta, Edmonton, Canada.

3) Commitee Member appointed by UK Cancer Institute for the conferring of Associate Professors of the University of Oxford, Inghilterra.

4) "Princess Margaret Cancer Centre" Committee, Therry Fox Foundation, Toronto, Canada.

5) Course of Biostatistics, McMaster University, Hamilton, Canada.

6) University of Tor Vergata, Roma/Regina Elena National Cancer Institute: "Master on Clinical and Translational Research on Gastric Tumors: Course of Molecular Biology".

7) Lectures at Harvard University, Boston, USA: "University Graduate School Courses. Translational Research Methods and Applications".

8) Lectures for PhD Students at University of Rome "La Sapienza", University of Trieste and University di Udine.

9) Member of EORTC Task Force on "GI cancers" and Task Force on "Translational Research".

TEACHING EXPERIENCE

Teacher Basic Science in Oncology (lectures) University La Sapienza (Rome, Italy).

Teacher, experimental course "Cell cycle and apoptosis", organized by the international School of Oncology and Experimental Medicine (Rome 1-4 December, 1994).

SUPERVISORSHIPS

Graduate Students

Sara Donzelli, M.Sc., University of Rome "La Sapienza", Faculty of Mathematical, Physical and Natural Sciences, 3 year Degree in Biological Science, Thesis entitled "Producing cancer cell lines expressing protein mutant p53 stability", Rome, Italy, 2002-2005.

Sara Donzelli, M.Sc., University of Rome "La Sapienza", Faculty of Mathematical, Physical and Natural Sciences, Specializing in Applied Biology in Biomedical Research, Thesis entitled "Oncogenomic Approaches in Exploring Gain ofFunction of Mutant p53", Rome, Italy, 2005-2007.

Federica Ganci, M.Sc., University of "Tor Vergata", Thesis entitled "The mutant protein p53His175 controls miR.128b expression in a human large-cell lung cancer cell line", Rome, Italy, 2007- 2008.

Olimpia Monti, M.Sc., University of "Tor Vergata", Thesis entitled "p73, p63 and mutant p53: members of protein complexes floating in cancer cells", Rome, Italy, 2001- 2002.

Ph.D Doctoral Students

Olimpia Monti, M.Sc., University of “Tor Vergata”, Ph.D Thesis entitled “The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs”, Rome, Italy, 2003- 2006.

Eleonora Lapi, M.Sc., University of “Tor Vergata”, Ph.D in Molecular and Cellular Biology, Thesis entitled “Identification of novel and direct target genes of p73”, Rome, Italy, 2004- 2007.

Efrem Bertini, M.Sc., University of “Tor Vergata”, Ph.D in Biochemistry and Molecular Biology, Thesis entitled “Yap is regulated by phosphorylation at the G2/M transition”, Rome, Italy, 2006- 2009.

Sara Donzelli, M.Sc., University of Rome “La Sapienza”, Faculty of Mathematical, Physical and Natural Sciences, Ph.D in Genetics and Molecular Biology, Thesis entitled “Study of mutant p53 protein gain of function by microRNAs modulation”, Rome, Italy, 2007-2011.

Sergio Galanti, M.Sc., University of Rome “La Sapienza”, Faculty of Biology and Biotechnology “Charles Darwin”, Ph.D in Cell and Developmental Biology, Thesis entitled “Identification of VDR transcriptional signatures in breast cancer cells by ChIP-on-chip analysis”, Rome, Italy, 2008-2011.

Federica Ganci, M.Sc., Ph.D in Celluar and Molecular Biology, Univeristy of Tor Vergata, Ph.D Thesis entitled “microRNAs expression profiling in HNSCC and their correlation with TP53 status”, Rome, Italy, 2008-2011.

Fabio Valenti, M.Sc., “University of Messina”, Faculty of Mathematical, Physical and Natural Sciences, Ph.D in Neuroscience, Medicine School University of Messina, Thesis entitled “Peptide targeted therapies for the treatment of human cancers with mutations of the p53 gene”, Messina, Italy, 2006-2010.

Francesca Fausti, Ph.D in Endocrinology and Molecular Medicine, Thesis entitled "Role of YAP in apoptosis and senescence processes", Rome, Italy, 2006-2010.

Francesca Biagioni, M.Sc., University of Rome “La Sapienza”, PhD school in Biology and Molecular Medicine, PhD programme in Immunological Sciences, Thesis entitled “The advent of microRNAs in the molecular taxonomy of breast cancer”, Rome, Italy, 2006-2009.

Stefania Dell’Orso, M.Sc., PhD in Endocrinology and Molecular Medicine, Faculty of Medicine, University of Rome “La Sapienza”, Thesis entitled “Application ofChIP on chip analysis to the identification of mutant p53 target genes”, Rome, Italy, 2006-2009.

Tania Frixa, Thesis entitled “MicroRNA-128-2 induces global microRNAs down-regulation through Drosha and Dicer depletion, promoting lung cancer cells oncogenic potential”, Rome, Italy, 2014-2017

Valeria Canu, Thesis entitled “MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer” Rome, Italy, 2014-2017

External Supervisory PhD Committees

Raffaela Santoro, Ph.D in Molecular Oncology, Thesis entitled "The Histone Acetyl Transferase Tip60 regulates the proapoptotic activities of the transcription factor E2F1", University of Southern Denmark, Odense, Denmark

2008 (Opponent).

Ying Zhao, Ph.D, Thesis entitled "Pharmacological Targeting of p53 Pathway Alterations in Tumors", Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden 2010 (Opponent).

Jinfeng Shen, Ph.D, Thesis entitled "Rescue of mutant p53 family members by the low molecular weight compound PRIMA-1MET/APR-246", Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden 2010 (Opponent).

Marco Napoli, Ph.D in Molecular Biomedicine, Thesis entitled "A Pin1/mutant p53 axis promotes aggressiveness in breast cancer", Università degli Studi di Trieste, Trieste, Italy 2010 (Opponent).

Erica Lorenzetto, PhD in Biomedical and Biotechnological Sciences, Thesis entitled: "Defining the role of YAP1 in 11q22-Amplified Cancer cell lines". University of Udine, Udine, Italia 2013 (opponent).

Sara Sessa, PhD in Biomedical and Biotechnological Sciences. Thesis entitled:"A "twist box" code of p53 inactivation in sarcomas". University of Udine, Udine, Italia 2013 (opponent).
Ilaria Castiglioni, PhD in Biomolecular Science, Thesis entitled " Development of drug screening assays for identification of new molecules against pancreatic ductal carcinoma" Università degli Studi di Trento, Trento, Italy, 2014 (opponent)

Giovanni Sorrentino, PhD in Molecular Biomedicine, Thesis entitled" Metabolic control of YAP and TAZ by the mevalonate pathway" Università degli Studi di Trieste, Italy, 2014 (opponent)

Carolanne Doherty, PhD in System Biology in Medicine, Thesis entitled" Characterisation of Yes-associated protein 1 signalling networks, biochemical and biological functions"University College Dublin, external examiner, Dublin, June 2015.

Supervision and external reviewer for students at the McMaster University

Linda Yang, Medical Student at 3H03 course. Proposal on "microRNAs as non coding mediators of metformin anticancer activities" Hamilton, Canada, June 2016.

Lillian Morgan, Medical Student at LIFESCI H403 course. Proposal on "microRNA as breast cancer long-term predictor biomarkers" Hamilton, Canada May 2017.

Grace Tang, Medical School Candidate Health Research and Methodology. Thesis on: Association of Metformin with Breast Cancer Incidence and Mortality: A systematic review and meta-analysis. September 2017.

ORGANIZATION OF INTERNATIONAL CONFERENCES

1) Making decisions in G1, Frascati, Italy 2002.
2) 1st International p73/p63 Workshop, Rome, Italy 2002.
3) 2nd International p73/p63 Workshop, Rome, Italy 2004.
4) P53 Marathon, Ein Gedi, Israel, 2005.
5) 3rd International p73/p63 Workshop, Rome, Italy 2007.

6) P53 Marathon, Lyon, France 2007.

7) P53 Marathon, Acre, Israel 2009;

8) The HIPPO Tumor Suppressor Pathway: Brainstorming Workshop, Rome, Italy 22-23 April, 2009. Published: Blandino G, Shaul Y, Strano S, Sudol M, Yaffe M. The Hippo tumor suppressor pathway: a brainstorming workshop. Sci Signal. 2009 Nov 3;2(95):mr6.

9) The 2nd Workshop on the HIPPO Tumour Suppressor Pathway, Ariccia (Rome), Italy, 2-5 November 2010. Published: McNeill H, Sudol M, Halder G, Strano S, Blandino G, Shaul Y. The Hippo tumor suppressor pathway: a report on "The Second Workshop On The Hippo tumor suppressor pathway". Cell Death Differ. 2011 Aug;18(8):1388-90.

10) 5th Mutant p53 Workshop: "From bench to bedside across mouse models", Ariccia (Rome), Italy, 24th May, 2011. Published: Blandino G, Deppert W, Hainaut P, Levine A, Lozano G, Olivier M, Rotter V, Wiman K, Oren M. "Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop". Cell Death Differ. 2012 Jan;19(1):180-3.

11) Keystone Symposium "The HIPPO Tumor Suppressor Network: from organ size control to stem cells and cancer", Monterey, CA, USA 19-23 May 2013 (Organizers: Dr. Sudol, Dr. Blandino, Dr. Halder, Dr. McNeil).

12) The HIPPO Pathway in Cancer. Rome, Italy April 15, 2014 (Organizers: Dr. Blandino, Dr. Fanciulli and Dr. Strano).

13) International Workshop on Metabolism, Diet and Chronic Disease: the perspective of cancer and cardiovascular disease prevention. Rome, Italy June 23, 2014 (Organizers: Dr. Blandino, Dr. Muti and Dr. Levrero).

14) The Epigen Workshop: Have OMICs approaches improved cancer deciphering and management? Rome, Italy October 27, 2015 (organizer: Dr. Blandino).

15) The 7th International Mutant p53 Workshop, Melbourne, Australia. October 26-28, 2016.

16) The 17th p53 Workshop, Singapore, July 8-12, 2017

17) The EMBO Workshop on HIPPO, Rome, October 25-29, 2017 (Organizers: Dr. N. Tapon, Dr. S. Piccolo and Dr. G. Blandino).

GRANT FUNDING

Principal Investigator

"Identification of novel coding and non-coding transcriprional targets of gain of function mutant p53" Euro 440.000. Finanziato da AIRC 2014-2016.

"Study of mutant p53-dependent epigenetic modifications in HNSCC" Blandino G, PI; Euros 300,000, Italian Ministry of Research and Italian National Council for Research (CNR) 2012-2014.

" Epigenetic and metabolic alterations in cancer pathogenesis" Blandino G, PI; Euros 400,000, Italian Ministry for Research and University 2011-2014 .

"Profile of microRNA expression and CpG Island methylation in tissue samples from mesothelioma patients" Blandino G, PI; Euros 600,000 Italian National Institute for Occupational Disease Prevention 2010-2012.

European Union 6th Framework "Integrated Project Active p53", Blandino

G,Scientific Coordinator; Euros 6,000,000.000 2004-2009 (extended 2012)

"Molecular signature as predictor of breast cancer occurrence" Blandino G, PI; Euros 150,000 Veronesi Foundation 2010-2012.

"p53 family interaction network as a target of anti-tumoral peptide therapy" Blandino G, PI; Euros 115.000 Pascale Foundation. 2008-2011.

"Exploring trascriptional activity of gain of function Mutant p53 protein" Blandino G, PI; Euros 330,000 AIRC. 2007-2011.

"Linking transcriptome to proteome: Functional oncogenomics for diagnosis and treatment of human cancer" Blandino G, PI; Euros 3,000,000 AIRC 2004-2011.

Co-Investigator

Identifying cooperating lesions of Mdm4/mutantp53 driven breast cancer and resistance mechanisms to Mdm4 inhibition. University of Texas MD Anderson Cancer Center Sister Institution Network Fund (SINF) Application. 2017-2019. Euros 60,000.

"Targeting the abnormal MicroRNA and Splicing Signatures in HIV-associated cancers". South African Medical Research Council (SAMRC) 2016

"Global epigenomic profiling of normal and diseased cells for the diagnosis of normal and diseased cells for diagnosis of hematological malignancies" Blandino G, Co-Investigator; Euros 120,000 Italian Ministry of Health 2010-2012

"New peptides as cell cycle regulators in chemotherapy for epithelial and skin cancer" Blandino G, Co-Investigator; Euros 150,000 Italian Institute for Dermatology 2007-2011

European Unnion 6th Framework: "Research unit of the Integrated Project "Mutp53" Prof. Klas Wiman and Prof. Moshe Oren (PI); Blandino G, Co-Investigator; Euros 240.933,50 2004

GRANT SUPPORT FOR THE CONDUCTION OF THE LABORATORY

The work in Dr. Blandino's laboratory is supported by:

Italian Ministry of Health: Euros 122,000.00

Italian Association for Cancer Research (AIRC): Euros 110,000.00

ACC-Italy-USA : Euros 90,000.00

Italian Ministry for Research and University: Euros 435,000.00

EPIGEN, Italian National Research Council and University: Euros 300,000.000

PATENTS, NATIONAL AND INTERNATIONAL

1. Inventors: Giovanni Blandino, Gennaro Citro, Rossella Maria Galati, Alessandra Verdina.
Number and date of deposit in Italy: MI2004A002227, 19 November 2004
This invention allows "Peptides to be able to break 53/p63, m-p53/p73 and m-p53/respective isoform proteins complex formed in the tumor cells and there uses in the pharmacological field". In addition, this invention uses a method that provokes the disruption of complex proteins found in the cancer cell lines in vitro. Furthermore, these peptides are used in preparing anti-cancer medicine.
Iter: 2007 Deposited permit request on a National/European level + permit requested in Israel, Singapore, the USA and EU. 2008 permit request made in Germany. 2010 Entered PCT national phase in the USA. 2011 Granted the

PCT process in Japan.

2.Inventors: Giovanni Blandino, Gennaro Citro, Sabrina Strano, Silvia Di Agostino.
Number and date of deposit in Italy: RM 2009A232 del 11/05/2009.
The present invention concerns peptide able to disrupt the protein complex between HIS273 mutated p53 protein and oncosuppressive p73 protein in tumor cells and uses hereof in medical field. More particularly, the present invention concerns a SIMP peptide (Short-interfering mutant p53 peptides) suitable to disrupt the protein complexes within tumor cells resulting from m-p53 and p73 proteins selectively in tumors wherein m-p53 contains HIS273 mutation. Iter: 2010 deposited international permit request.

PUBLICATIONS IN PEER-REVIEWED JOURNALS:

H-index = 43 (calculated with Scopus).

Citations: 6420

1) Callari D, Gasso G, **Blandino G**, Billitteri A. Azione del retinolo su colture di hepatoma H4. Boll. Soc. It. Biol. Sper. N11, 1989.

2) Callari D, **Blandino G**, Saccone V, D'Amico C, Billitteri A. Azione del retinolo sul recupero di cellule vitali e sul potenziale clonogenico di cellule HTC ipertermizzate in vitro. Boll. Soc. It. Biol. Sper. N.12, 1992.

3) Callari D, **Blandino G**, Saccone V, D'Amico C, Billitteri A. Azione dell'ipertermia e del trattamento con retinolo in vitro sull'adesività alla laminina ed alla fibronectina delle cellule HTC. Boll. Soc. It. Biol. Sper. N.12; 1992.

4) Callari D, Strano S, **Blandino G**, Saccone V, and Billitteri A. Adhesion to some extracellular matrix components of heat-treated HTC hepatoma cells. J. Exp. Clin. Cancer. Res. 13: 2, 1994.

5) Strano S, Callari D, Billitteri A, and **Blandino G**. Fibronectin and Vitronectin Adhesion enhancement during U937 cells differentiation induced by IL-6 and LIF. J. Exp. Clin. Cancer Res., 13, 4, 1994.

6) Soddu S, **Blandino G**, Citro G, Scardigli R, Piaggio G, Ferber A, Calabretta B, and Sacchi A. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood, 83, 8, 1994.

7) Strano S, and **Blandino G**. Apoptosis: cell death or suicide. This is the problem! J. Exp. Clin. Cancer Res., 14, 3, 1995.

8) **Blandino G**, Scardigli R, Rizzo MG, Crescenzi M. Soddu S, and Sacchi A. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells. Oncogene, 10, 731-737, 1995.

9) Soddu S, **Blandino G**, Scardigli R, Martinelli R, Rizzo MG, Crescenzi M, and Sacchi A. WT-p53 induces diverse effects in 32D cells expressing different oncogenes. Molecular and Cellular Biology, 16, 2, 487-495, 1996. (The two first authors contributed equally to this work).

10) Soddu S, **Blandino G**, Scardigli R, Coen S, Marchetti A, Rizzo MG, Bossi G, Cimino L, Crescenzi M, and Sacchi A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. The Journal of Cell Biology, 134, 1, 193-204, 1996.

11) Martinelli R, **Blandino G**, Scardigli R, Crescenzi M, Lombardi D, Sacchi A, and Soddu S. Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. Oncogene 15, 607-611, 1997.

12) Shaulian E, Resnitzky D, Shifman O, **Blandino G**, Amsterdam A, Yayon A, and Oren M. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 15, 2717-2725, 1997.

13) Scardigli R, Bossi G, **Blandino G**, Crescenzi M, Soddu S, and Sacchi A. Exogenous wt-p53 overexpression does not affect normal hematopoiesis: basis for bone marrow purging? Gene Therapy 4, 1371-1378, 1997.

14) **Blandino G**, and Strano S. Bcl-2: the pendolum of the cell fate. J. Exp. Clin. Cancer. Res., 16, 1, 1997.

15) Rizzo M.G, Zepparoni A, Cristofanelli B, Scardigli R, Crescenzi M, **Blandino G**, Giuliacci S, Ferrari S, Soddu S and Sacchi A. Wtp53-action in human leukemia cell lines corresponding to different stages of differentiation. British Journal of Cancer 77, 1429-1438, 1998.

16) Wang Y, **Blandino G**, Oren M, and Givol D. Induced p53 expression in lung cancer cell line promotes cell senescence and differently modifies the cytotoxicity of anticancer drugs. Oncogene 17, 1923-1930, 1998.

17) **Blandino G**, Levine AJ, and Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18, 477-485, 1999.

18) Wang Y, **Blandino G**, and Givol D. Induced p21 waf1 expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene 18, 2643-2649, 1999.

19) Agami R, **Blandino G**, Oren M, Shaul Y. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature 399, 809-813, 1999.

20) Cerone M.A, Marchetti A, Bossi G, **Blandino G**, Sacchi A, and Soddu S. p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblast. Cell Death and Differentiation 7, 506-508, 2000.

21) Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine A.J, Sacchi A, Cesareni G, Oren M and **Blandino G**. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275, 29503-29512, 2000.

22) Strano S, Rossi M, Fontemaggi G, Munarriz E, Soddu S, Sacchi A and Blandino G. From p63 to p53 across p73. FEBS Letters, 490, 163-170, 2001.

23) Strano S, Munarriz E, Rossi M, Cristofanelli B, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G and Blandino G. Physical interaction with Yes-associated protein (YAP) enhances p73 transcriptional activity. J. Biol.Chem., 276, 15164-15173, 2001.

24) Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, and Blandino G. The transcriptional repressor ZEB regulates p73 expression at the cross-road between proliferation and differentiation. Mol. Cell. Biol., 24, 8461-8470, 2001.

25) Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole P, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, and Levrero M. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell, 9, 175-186, 2002.

26) Le Bras M, Delattre V, Bensaad K, Blandino G, and Soussi T. Monoclonal antibodies raised against Xenopus p53 interact with human p73. Oncogene,14, 1304-1308, 2002.

27) Morena A.R, Riccioni S, Marchetti A, Tartaglia Polcini A, Mercurio A.M, Blandino G, Sacchi A, and Falcioni R. Expression of β4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells. Blood, 100, 96-106, 2002.

28) Strano S, Fontemaggi G, Costanzo A, Rizzo M.G, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M and Blandino G. Physical interaction with human tumor derived p53 mutants inhibits p63 activities. J. Biol Chem. 277, 18817-18826, 2002.

29) Fontemaggi G, Kela I, Amariglio N, Rechavi G, Krishnamurthy J, Strano S, Sacchi A, Givol D, and Blandino G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J. Biol Chem. 277, 43359-43368, 2002.

30) Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C, and Del Sal G. The Prolyl-Isomerase Pin1 reveals a new mechanism to control p53 functions following genotoxic insults. Nature, 419, 853-857, 2002.

31) Bensaad K, Le Bras M, Unsal K, Strano S, BlandinoG, Tominaga O, Rouillard D and Soussi T. Change of conformation of the DNA binding domain of p53 is the only key element for binding and interfering with p73. J. Biol. Chem. 278, 10546-10555, 2003.

32) Strano S, and Blandino G. p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53 proteins. Cell Cycle 2, 348-349, 2003.

33) Fulco M, Costanzo A, Merlo P, Mangiacasale R, Strano S, Blandino G, Balsano C., Lavia P, and Levrero M. p73 is regulated by phosphorylation at

the transition G2/M. J. Biol. Chem., 278, 49196-49202, 2003.

34) Di Stefano V, **Blandino G**, Sacchi A, Soddu S, and G. D' Orazi. HIPK2 counteracts MDM2 inhibition of p53 by interfering with its ubiquitination and nuclear export. Oncogene 231, 5185-5192, 2004.

35) Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, **Blandino G**, and Del Sal G. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Molecular Cell, 14, 625-636, 2004.

36) **Blandino G** and M. Dobbelstein. p73 and p63-why do we still need them? Cell Cycle 3, 886-894, 2004.

37) Rizzo M.G, Giombini E, Diverio D, Vignetti M, Testa U, Sacchi A, Lo Coco F, and **Blandino G**. Analysis of p73 expression in acute myeloid leukemias: lack of DN-p73 expression is a frequent feature of acute promielocytic leukemia. Leukemia 18, 1804-1809, 2004.

38) Dobbelstein M, Strano S, Roth J, and **Blandino G**. p73-induced apoptosis: a question of compartments and cooperation. Biochem. Biophys. Res. Commun, 331, 688-693, 2005.

39) Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, and **Blandino G**. The transcriptionl co-activator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Molecular Cell. 18, 447-459, 2005.

40) Fontemaggi G, Gurtner A, Damalas A, Higashi Y, Sacchi A, Strano S, Piaggio G and **Blandino G**. δEF1 repressor controls selectively p53 family members during differentiation. Oncogene. Nov. 10; 24(49):7273-80, 2005.

41) Merlo P, Fulco M, Costanzo A, Mangiacasale R, Strano S, **BlandinoG**, Taya Y, Lavia P. and Levrero M.p73 role in mitotic exit. J. Biol. Chem. 280, 30354-30360, 2005.

42) Bossi G, Lapi E, Strano S, Rinaldo C, **Blandino G**, and Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene Jan 12 ; 25 (2):304-9, 2006.

43) Belloni L, Moretti F, Damalas A, Costanzo A, **Blandino G**, and Levrero M. ΔNp73α protects myogenic cells from apoptosis. Oncogene Jun.15 ;25 (25):3606-12, .2006.

44) Lapi E, Iovino A, Fontemaggi G, Soliera R, Iacovelli S, Sacchi A, Rechavi G, Givol D, **Blandino G*** and Strano S. S100A2 is a direct transcriptional target of p53 homologues during keratynocyte differentiation (*corresponding author) Oncogene Jun.22 ;25 (26):3628-37, 2006.

45) Giombini E, **Blandino G**, Sacchi A, Lo Coco F, and Rizzo M.G. The

complexity of p73 isoforms in human neoplasia. Gene Ther. Mol. Biol. 9:1-16, 2005.

46) Hoshino M, Qi M, YoshimuraM, MiyashitaT., TagawaK, WadaY, EnokidoY, Marubuchi S, Harjesv P, Arai N, Oyanagi K, **Blandino G**, Sudol M, Rich T, Kanazawa I, Wanker E, Saitoe M, and Okazawa H. Transcriptional repression induces a slowly progressive atypical neuronal death associated with changes of YAP isoforms and p73. J. Cell Biology Feb. 589-604, 2006.

47) Di Agostino S, Strano S, Emiliozzi V, Sacchi A, **Blandino G***, Piaggio G. Gain of function of mutant p53: the mutant p53/NFY protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. (*corresponding author) Cancer Cell Sep.10 (3):191-202, 2006.

48) Strano S, Dell'Orso S, Mongiovì A, Monti O, Lapi E, Di Agostino S, Fontemaggi G and **Blandino G**. Mutant p53 proteins: between loss and gain of function. Head and Neck 29:488-96, 2007.

49) Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, and **Blandino G**. Mutant p53: an oncogenic transcription factor. Oncogene 26:2212-9, 2007.

50) Weisz L, Damalas A, Liontos M, KarakaidosP, FontemaggiG, KalisM, Levrero M, Strano S, Gorgoulis W.G, Rotter V, **Blandino G**, Oren M. Mutant p53 enhances NF-kB activation by tumor necrosis factor alpha in cancer cells. Cancer Research 67:2396-401, 2007.

51) **Blandino G**, Fanciulli M, Levrero M, Piaggio G. The Post Genomic Era: Workshop on Chromatin Immunoprecipitation related techniques. Cell. Death and Diff. 14:1390-1391, 2007.

52) Mainardi S, Palescandolo E, Fontemaggi G, Diverio D, Grignani F, Testa U, Sacchi A, Lo Coco F, Levrero M, **Blandino G*** and Rizzo MG. DNp73 is a transcriptional target of PML/RARαoncogene (*corresponding author) Cell Death and Differentiation 14:1968-71, 2007.

53) Strano S, and **Blandino G**. YAP meets tumor suppression. Mol. Cell, 27:863-4, 2007.

54) Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, **Blandino G**, Givol D, D'Orazi G. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res. May 15;68(10):3707-14, 2008.

55) Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, **Blandino G**, Sacchi A. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle. Jun 15;7(12):1870-9, 2008.

56) Di Agostino S, Cortese G, Monti O, Dell'Orso S, Sacchi A, Eisenstein M, Citro G, Strano S, **Blandino G**.The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle. Nov 1;7(21):3440-7, 2008.

57) **Blandino G**. Mitosis poisons p53. Cell Cycle. Nov 1;7(21), 2008.

58) Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G, Pandolfi PP, Givol D, Strano S, Lu X, **Blandino G**. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop.Mol Cell. Dec 26;32(6):803-14, 2008.

59) Donzelli S, Biagioni F, Fausti F, Strano S, Fontemaggi G, **Blandino G**. Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. Curr Genomics. May;9(3):200-7, 2008.

60) Benassi B, Strano S, **Blandino G**. Tetraploidy triggers mitochondria. Cell Cycle. May 1;8(9):1305-6, 2009.

61) **Blandino G**, Moll UM. p63 regulation by microRNAs. Cell Cycle. May5;8(10):1466-7, 2009.

62) Haupt S, Di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, **Blandino G**, Haupt Y. Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res. Jun 1;69(11):4818-26, 2009.

63) Bertini E, Oka T, Sudol M, Strano S, **Blandino G**. YAP: at the crossroad between transformation and tumor suppression. Cell Cycle. Jan 1;8(1):49-57, 2009.

64) Bon G, Di Carlo SE, Folgiero V, Avetrani P, Lazzari C, D'Orazi G, Brizzi MF, Sacchi A, Soddu S, **Blandino G**, Mottolese M, Falcioni R. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. Cancer Res. Jul 15;69(14):5978-86, 2009.

65) Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, **Blandino G**.Metformin, diet and breast cancer: an avenue for chemoprevention. Cell Cycle. Aug 15;8(16):2661, 2009.

66) Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, Testa U, Pelosi E, Piaggio G, Sacchi A, Lavorgna S, Lo-Coco F, **Blandino G**, Levrero M, Rizzo MG. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene. Nov 12;28(45):4034-40, 2009.

67) Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, **Blandino G**. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol. Oct;16(10):1086-93, 2009.

68) Muscolini M, Montagni E, Caristi S, Nomura T, Kamada R, Di Agostino S, Corazzari M, Piacentini M, **Blandino G**, Costanzo A, Sakaguchi K, Tuosto L. Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle. Oct 15;8(20):3396-405, 2009.

69) Barba M, Yang L, Schünemann HJ, Sperati F, Grioni S, Stranges S, Westerlind KC, **Blandino G**, Gallucci M, Lauria R, Malorni L, Muti P. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res. Oct 8;28:135, 2009.

70) **Blandino G**, Shaul Y, Strano S, Sudol M, Yaffe M. The Hippo tumor suppressorpathway: a brainstorming workshop. Sci Signal. Nov 3;2(95):mr6, 2009.

71) Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Sigfried Z, Shiff I, Kogan I, Shay M, Kalo E, **Blandino G**, Simon I, Oren M, Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell. Mar 16;17(3):273-85, 2010.

72) Avraham R, Sas-Chen A, Manor O, Steinfeld I, Shalg Ri, Tarcic G, Bossel N, Zeisel A, Amit I, Enerly E, Russnes HG, Biagioni F, Mottolese M, Strano, **Blandino G**, Børresen-Dale A, Pilpel Y, Yakhini Z, Segal E and Yarden Y. EGF Decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci. Signal. Jun 1;3(124):ra43, 2010.

73) Cioce M, Gherardi S, Viglietto G, Strano S, **Blandino G**, Muti P and Ciliberto G. Enriched mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like targeting drugs. Cell Cycle. Jul 15;9(14):2878-87, 2010.

74) Bruno T, Desantis A, Bossi G, Di Agostino S, Sorino C, De Nicola F, Iezzi S, Franchitto A, Benassi B, Floridi A, Passananti C, **Blandino G**, and Fanciulli M. Che-1 depletion inhibits mutant p53 expression and activates p73-dependent apoptsosis by inducing endogenous DNA damage in human breast cancer. Cancer Cell. Aug 9;18(2):122-34, 2010.

75) Slee E, Benassi B, Goldin R, Zhong S, **Blandino G**, and Lu X. Phosphorylation of Ser312 contributes to tumour suppression by p53 in vivo. Proc Natl Acad Sci U S A. Nov 9;107(45):19479-84, 2010.

76) Santoro R, **Blandino G**. p53: The pivot between cell cycle arrest and senescence.Cell Cycle. Nov;9(21):4262-3, 2010.

77) Fontemaggi G, Dell'Orso S, Muti P, **Blandino G** and Strano S. Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle. Jun 15;9(12):2464-6, 2010.

78) Strano S and **Blandino G**. Stability strengths oncogenic activity.Cell Cycle. Apr 15;9(8):1458-9, 2010.

79) Goeman F, **Blandino G**. Novel insights into the cytoplasmic functions of

p53. Cell Cycle. Jul 1;9(13):2498, 2010.

80) Dell'Orso S, Ganci F, Strano S, **Blandino G**, and Fontemaggi G. ID-4: a new player in the cancer arena. Oncotarget. May;1(1):48-58, 2010.

81) Di Agostino S, Strano S, **Blandino G**. YAP1 (Yes-associated protein 1, 65kDa). Atlas Genet Cytogenet Oncol Haematol. January 2010.

Publications 2011

82) Dell'Orso S, Fontemaggi G, Stambolsky P, Goeman F, Voellenkle C, Damalas A, Levrero M, Strano S, Rotter V, Oren M and **Blandino G**. ChIP on chip analysis of in vivo mutantp53 binding to selected gene promoters. OMICS. May;15(5):305-12, 2011.

83) Muti P, Benassi B, Falvo E, Santoro R, Galanti S, Citro G, Carrubba G,

Blandino G, and Strano S. Omics underpins novel clues on VDR chemoprevention target in breastcancer. OMICS. Jun;15(6):337-46, 2011.

84) Ganci F, Conti S, Fontemaggi G, Manciocco V, Donzelli S, Covello R, Muti P, Strano S, **Blandino G**, Spriano G. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors. OMICS. Jun;15(6):375-81, 2011.

85) Testoni B, Guerrieri F, Gerbal-Choine S, **Blandino G** and Levrero M. p53-paralog DNp73 oncogene is repressed by IFNα/STAT2 through the recruitment of the Ezh2 Polycomb Group transcriptional repressor. Oncogene. Jun 9;30(23):2670-8, 2011.

86) Sieri S, Muti P, Agnoli C, Berrino F, Pala V, Grioni S,Abagnato CA, **Blandino G**, Contiero P, Schunemann H, Krogh V. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer. Feb 15;130(4):921-9, 2011.

87) Testoni B, Voellenke C, Guerrieri F, Gerbal-Chaloin S, **Blandino G**, Levrero M. Chromatin dynamics of gene activation and repression in response to ifn{alpha} reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. J Biol Chem. Jun 10;286(23):20217-27, 2011.

88) McNeill H, Sudol M, Halder G, Strano S, **Blandino G**, Shaul Y.Meeting Report The Hippo tumor suppressor pathway: a report on the Second Workshop on the Hippo tumor suppressor pathway. Cell Death Differ. Aug;18(8):1388-90, 2011.

89) Muscolini M, Montagni E, Palermo V, Di Agostino S, Gu W, Abdelmoula-Soussi S, Mazzoni C, **Blandino G** and Tuosto L. The cancer-associated K351N mutation affects the ubiquitination and the translocation to mitochondria of p53 protein. J Biol Chem. Nov 18;286(46):39693-702, 2011.

90) Botti E, Spallone G, Moretti F, Marinari B, Pinetti V, Galanti S, De Meo PD, De Nicola F, Ganci F, Castrignanò T, pesole G, Chimenti S, Guerrini L,

Fanciulli M, Blandino G, Karin M, Costanzo A. Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Proc Natl Acad Sci U S A. Aug 16;108(33):13710-5, 2011.

91) Falvo E, Strigari L, Citro G, Giordano C, Arcangeli S, Soriani A, D'Alessia D, Muti P, Blandino G, Sperduti I, Pinnarò P. Dose and polymorphic genes xrcc1, xrcc3, gst paly a role in the risk of article developing erythema in breast cancer patients following single shot partial breast irradiation after conservative surgery. BMC Cancer. Jul 12;11:291, 2011.

92) Cioce M, Blandino G. PGC1α Confers Specificity - Metabolic Stress and p53-Dependent Transcription. Molecular Cell. Nov 18;44(4):515-6, 2011.

Publications 2012

93) Santoro R, Marani M, Blandino G, Muti P, Strano S. Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. Oncogene. Jun 14;31(24):2931-42, 2012.

94) Blandino G, Deppert W, HainautP, Levine A, Lozano G, Olivier M, Rotter V, WimanK and Oren M. Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop. Cell Death & Differentiation.Jan;19(1):180-3, 2012.

95) Canino C, Mori F, Cambria A, Diamantini A,Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, Facciolo F, Citro G, Strano S, Muti P, Blandino G, Cioce M. SASP mediates chemoresistance and tumor-initiating-activity of Mesothelioma cells. Oncogene. Jun 28;31(26):3148-63, 2012.

96) Cioce M, Canino C, Muti P, Strano S, Blandino G. Butein impairs the pro-tumorigenic activity of malignant pleural mesothelioma cells. Cell Cycle.Jan 1;11(1):132-40, 2012.

97) Benassi B, Flavin R, Marchionni L, PanY, Chowdhury D, Marani M, Strano S, Muti P, Blandino G, and Loda M. c-Myc is activated via USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discov. Mar;2(3):236-247 (co-corresponding author), 2012.

98) Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G. microRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death and Differentiation Jun;19(6):1038-48, 2012.

99) Valenti F, Fausti F, Biagioni F, Fontemaggi G, Shay T, Domany E, Yaffe MB, Strano S, Blandino G, Di Agostino S. Mutant p53 oncogenic functions are sustained by plk2 kinase through an autoregulatory feedback loop. Cell Cycle. Dec 15;10(24):4330-40, (co-corresponding author), 2012.

100) Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Bergamo P, Anichini A, Sabapathy K, McCubrey J, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, Cognetti F, De Maria R, Del Bufalo D, Milella M. The mitogen activated protein kinase (MARK) cascade

controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J Mol Med (Berl). 2012 Jun;90(6):667-79. 2012.

101) Falvo E, Strigari L, Citro G, Giordano C, Boboc G, Fabretti F, Bruzzaniti V, Bellesi L, Muti P, **Blandino G**, Pinnarò P. SNPs in DNA repair or Oxidative Stress Genes and Late Subcutaneous Fibrosis in Patients following a Single Shot Partial Breast Irradiation. JECCR.Jan 24;31:7, 2012.

102) **Blandino G***, Valerio M, Cioce M, Mori F, Casadei L, Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S, Manetti C, Gennaro Citro G, Muti P, Strano S. Metformin elicits anticancer effects through the sequential modulation of DICER, microRNAs and c-MYC. Nat Commun. May 29;3:865 (*corresponding author), 2012.

103) Cordelli, E, Eleuteri, P, Grollino, M, Benassi, B, Blandino, G, Bartoleschi, C, Pardini, M, Di Caprio, E, Spanò, M, Pacchierotti, F, Villani, P. Direct and delayed X-ray induced DNA damage in male mouse germ cells. Environ Mol Mutagen. Jul;53(6):429-39, 2012.

104) Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E and **Blandino G**. miR-10b*, a master inhibitor of the cell cycle, is downregulated in human breast tumors. EMBO Mol Med. Nov;4(11):1214-29, 2012.

105) Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A., and **Blandino G**. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis. Nov 15;3:e423, 2012.

106) Fausti F, Di Agostino S, Sacconi A, Strano S, **Blandino G**. Hippo and rassf1a Pathways: A Growing Affair. Mol Biol Int. 2012:307628, 2012.

Publications 2013

107) Santoro R, Marani M, **Blandino G**, Muti P, Strano S. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. Carcinogenesis. May;34(5):1051-61, 2013.

108) Strano S., Fausti F., Di Agostino S., Sudol M., and **Blandino G**. PML surfs into the HIPPO Tumor Suppressor Pathway. Front Oncol. Mar 1;3:36, 2013.

109) Di Agostino S, Strano S, and **Blandino G**. Gender, mutant p53 and PML: A growing "affaire" in tumor suppression and oncogenesis. Cell Cycle, 12, 1824-5 2013.

110) Mori F, Strano S, and **Blandino G**. MicroRNA 181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. Cell Cycle 12, 1823-4, 2013.

111) Biagioni F, Bossel-Moshe N, Fontemaggi G, Yarden Y, Domany E, and Blandino G.The locus of micro-RNA10b: a critical target for breast cancer insurgence and dissemination. Cell Cycle 12, 2371-5, 2013.

112) Schernhammer SV, Sperati F, Razavi P, Agnoli C, Sieri S, Berrino F, Krogh V, Abbagnato CA, Grioni S, Blandino G, Schunemann JH, Muti P. Endogenous sex steroids in premenopausal women and risk of breast cancer: the ORDET cohort. Breast Cancer Res. 15, R46, 2013.

113) Benassi B, Marani M, Loda M, and Blandino G. USP2a alters chemotherapeutic response by modulating redox. Cell Death and Disease,4 e-812, 2013.

114) Fausti F, Di Agostino S, Cioce M, Bielli P, Sette C, Pandolfi PP, Oren M, Sudol S, Strano S, and Blandino G. ATM-kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner-mediated oncogenic senescence. Cell Death and Diff. 20, 1498-509, 2013.

115) Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, Muti P, Strano S, Spriano G, Fontemaggi G, and Blandino G. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head & neck squamous cell carcinoma patients. Annals of Oncology, 24, 3082-8, 2013.

116) Pulito C, Sanli T, Ranam P, Muti P, Blandino G, and Strano S. Metformin: an ongoing journey across diabetes, cancer therapy and prevention. Metabolites. Nov 7;3(4):1051-75, 2013.

117) Fazi F, and Blandino G. microRNAs: non coding pleiotropic factors in development, cancer prevention and treatment. Microrna. 2(2):81, 2013.

Publications 2014

118) Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, and Blandino G. Gain of function mutant p53 downregulates miR-223 contributing to chemoresitance of tumor cells. Oncogene. Mar 20;33(12):1601-8, 2014.

119) Cappuzzo F, Sacconi A, Landi L, Ludovini V, Biagioni F, D'Incecco A, Capodanno A, Salvini J, Corgna E, Cupini S, Fontanini G, Crinò L, Blandino G. MicroRNA signature predicts sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer. Clin Colorectal Cancer. Mar;13(1):37-45.e4, 2014.

120) Cioce, M., Ganci F., Canu V., Sacconi, Mori F., Canino C., Korita E., Casini B., Alessandrini G., Cambria A., Carosi M., Blandino. R., Panebianco V., Facciolo F., Volinia S., Muti, P., Strano, S., Croce, C., Pass, H., and Blandino G. Protumorigenic effects of miR-145 loss in Malignant Pleural Mesothelioma. Oncogene. Nov 13;33(46):5319-31, 2014.

121) Blandino G*, Fazi F, Donzelli S, Kedmi M, Sa-Chen A, Muti P, Strano S, and Yarden Y. Tumor Suppressor MicroRNAs: a novel non-coding alliance against cancer.FEBS Lett. 2014 Aug 19;588(16):2639-2652.(* corresponding author), 2014.

122) Goeman F, De Nicola F, De Meo P.D, Elmi, B, Castrignanò T, Pesole G, Strano S, Blandino G, Fanciulli M and Muti P. VDR primary targets by genome-wide transcriptional profiling. J Steroid Biochem Mol Biol. Apr 13;143C:348-356, 2014.

123) Canu V, Blandino G*, Lorenzon L. Research on microRNAs leads to new frontiers of clinical and translational relevance for gastric cancer management. Translational Gastronintestinal Cancer.Vol 3, No 2, April. (*corresponding author), 2014.

124) Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S, and Blandino G. MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Ther. 2014 Jun 1;2:16, 2014.

125) Dinami R, Ercolani C, Piazza S, Ciani Y, Petti E, Sacconi A, Biagioni F, le Sage C, Agami R, Benetti R, Mottolese M, Schneider C, Blandino G, Schoeftner S. miR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Res. Aug 1;74(15):4145-56, 2014.

126) Ganci F, Vico C, Korita E, Sacconi A, Gallo E, Mori F, Cambria A, Russo E, Anile M, Vitolo D, Pescarmona E, Blandino R, Facciolo F, Venuta F, Blandino G, Marino M, Fazi F. MicroRNAs Expression Profiling of Thymic Epithelial Tumors. Lung Cancer, Aug;85(2):197-204, 2014.

127) Santini S, Di Agostino S, Coppari E, Bizzarri A.R, Blandino G, Cannistaro S. Interaction of mutant p53 with p73: A surface plasmon resonance and atomic force spectroscopy study. Biochim Biophys Acta. Jun;1840(6):1958-64, 2014.

128) Cioce M, Valerio MC, Casadei L, Pulito C, Sacconi A, Mori F, Biagioni F, Muti P, Strano S, and Blandino G. Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. Oncotarget. Jun 30;5(12):4129-43, 2014.

129) Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, Ten Hacken E, Bertilaccio S, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson P, Carrasco R, Kimmelman AC, Wong K, Caligaris-Cappio F, Blandino G, Kuehl V, Anderson KC, and Tonon G. Rescue of YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nature Medicine, Jun;20(6):599-606, 2014.

130) Bashk S, and Blandino G. Tumor Suppression. Editorial in FEBS Letters, Aug 19;588(16):2557, 2014.

131) Donzelli S, Strano S, and Blandino G. MicroRNAs: short non-coding bullets of gain of function mutant p53 proteins. Oncoscience. 2014 Jun 7;1(6):427-33, 2014.

132) Pulito C, Donzelli S, Muti P, Puzzo L, Strano S, and **Blandino G**. microRNAs and cancer metabolism reprogramming: the paradigm of metformin. Ann Transl Med. Jun;2(6):58, 2014.

133) Muti P, Sacconi A, Hossain A, Donzelli S, Bossel N, Ganci F, Sieri S, Krogh V, Berrino F, Biagioni F, Strano S, Beyene J, Yarden Y, **Blandino G**. Downregulation of microRNAs 145-3p and 145-5p is a Long-Term Predictor of Postmenopausal Breast Cancer Risk: the ORDET prospective study. Cancer Epidemiol Biomarkers Prev. Nov;23(11):2471-81, 2014.

134) Ganci F, Sacconi A, Manciocco V, Sperduti I, Battaglia P, Covello R, Muti P, Strano S, Spriano G, Fontemaggi G, and **Blandino G**. microRNAs expression as predictor of local recurrence risk in oral squamous cell carcinoma. Head Neck. 2014 Dec 22. doi: 10.1002/hed.23969. [Epub ahead of print]

Publications 2015

135) Valenti F, Ganci F, Fontemaggi G, Strano S, **Blandino G***, and Di Agostino S. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptional downregulate BRCA1 and RAD17 gene expression. Oncotarget. Mar 20;6(8):5547-66. (*co-corresponding author), 2015.

136) Mori F, Sacconi A, Canu V, Ganci F, Novello M, Anelli V, Covello R, Ferraresi V, Muti P, Biagini R, **Blandino G***, and Strano S. miR-181c associated with relapse of high grade osteosarcoma. Oncotarget. Jun 10;6(16):13946-61.(*corresponding author), 2015.

137) Fiorini C, Cordani M, Padroni C, **Blandino G**, Di Agostino S, Donadelli M. Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Biochim Biophys Acta. Jan;1853(1):89-100, 2015.

138) Kedmi M, Ben-Chetrit N, Körner C, Mancini M, Ben-Moshe NB, Lauriola M, Lavi S, Biagioni F, Carvalho S, Cohen-Dvashi H, Schmitt F, Wiemann S,**Blandino G**, Yarden Y. EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Sci Signal. Mar 17;8(368):ra29, 2015.

139) Adi Harel S, Bossel Ben-Moshe N, Aylon Y, Bublik DR, Moskovits N, Toperoff G, Azaiza D, Biagoni F, Fuchs G, Wilder S, Hellman A, **Blandino G**, Domany E, Oren M. Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth. Cell Death Differ. 2015 Aug;22(8):1328-40, 2015.

140) Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Gentileschi MP, Germoni S, Monteleone V, Pellegrino M, Kann M, De Meo PD, Pallocca M, Höpker K, Moretti F, Mattei E, Reinhardt HC, Floridi A, Passananti C, Benzing T, **Blandino G**, Fanciulli M. Che-1 modulates the decision between cell cycle arrest and apoptosis by its binding to p53. Cell Death Dis. May 21;6:e1764, 2015.

141) Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Ponzoni M, Bossi G, Federico V, La Rosa F, Ricciardi MR, Lesma E, De Meo PD, Castrignanò T, Petrucci MT, Pisani F, Chesi M, Bergsagel PL, Floridi A, Tonon G, Passananti C, **Blandino G**, Fanciulli M.

Che-1-induced inhibition of mTOR pathway enables stress-induced autophagy. EMBO J. May 5;34(9):1214-30, 2015.

142) O'Brien AJ, Villani LA, Broadfield LA, Houde VP, Galic S, **Blandino G**, Kemp BE, Tsakiridis T, Muti P, Steinberg GR. Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. Biochem J. Jul 15;469(2):177-87, 2015.

143) Canino C, Luo Y, Marcato P, **Blandino G**, Pass H and Cioce M. A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations. Oncotarget. May 20;6(14):12637-53, 2015.

144) Pulito C, Terrenato I, Di Benedetto A, Sacconi A, Biagioni F, **Blandino G**, Strano S, Muti P, Mottolese M, and Falvo E. Cdx2 VDR polymorphism affects the activities of Vitamin D Receptor in human breast cancer cell lines and human breast carcinomas. PLoS One. Apr 7;10(4):e0124894, 2015.

145) Fontemaggi G, Bellissimo T, Donzelli S, Iosue I, Benassi B, Bellotti G, **Blandino G***, Fazi F. Identification of post-transcriptional regulatory networks during myeloblast-to-monocyte differentiation transition. RNA Biol. 12(7):690-700, 2015. (*co-corresponding author)

146) Pulito C, Mori F, Sacconi A, Casadei L, Ferraiuolo M, Valerio MC, Santoro R, Goeman F, Maidecchi A, Mattioli L, Manetti C, Di Agostino S, Muti P, **Blandino G** and Strano S. Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion. Oncotarget. Jul 20;6(20):18134-50, 2015.

147) Donzelli S, Mori F, Bellissimo T, Sacconi A, Casini B, Frixa T, Roscilli G, Aurisicchio L, Facciolo F, Pompili A, Carosi MA, Pescarmona E, Segatto O, Pond G, Muti P, Telera S, Strano S, Yarden Y and **Blandino G.** Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget. Nov 3;6(34):35183-201, 2015.

148) Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, Piazza S, Strano S, Del Sal G, **Blandino G**. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep. 2016 Feb;17(2):188-201.

149) Bellissimo T, Russo E, Ganci F, Vico C, Vitolo D, Anile M, Disio D, **Blandino G**, Venuta F, and Fazi F. Circulating miR-21-5p and 148a-3p as emerging non-invasive biomarkers in thymic epithelial tumors. Cancer Biol Ther. 2016;17(1):79-82.

150) Strano S, Muti P and **Blandino G**. What biomarkers (if any) for precise medicine? Aging (Albany NY). Aug; 7(8):533-4, 2015.

151) Frixia T, Donzelli S, and **Blandino G**. Oncogenic microsRNAs: key players in malignant transformation. Cancers (Basel). Dec 18;7(4):2466-85, 2015.

152) Sestito R, Cianfrocca R, Rosanò L, Tocci P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A, **Blandino G**, Bagnato A. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget. 2016 Jan 26;7(4):4009-23.

152) Donzelli S, Cioce M, Muti P, Strano S, Yarden Y and **Blandino G**. MicroRNAs: non-coding fine tuners of receptor tyrosine kinase signaling in cancer. Semin Cell Dev Biol. 2016 Feb;50:133-42.

153) Mori F, Ferraiuolo M, Santoro R, Sacconi A, Goeman F, Pallocca M, Pulito C, Korita E, Fanciulli M, Muti P, **Blandino G*** and Strano S. Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. (*co-corresponding author). Oncotarget. 2016 Apr 12;7(15):20532-48.

154) Ferraioulo M, Di Agostino S, **Blandino G** and Strano S. Oncogenic intra-p53 family interactions in human cancers. Front Oncol. 2016 Mar 31;6:77.

155) Aggarwal M, Saxena R, Sinclair E, Fu Y, Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B, Mueller SC, Di Agostino S, **Blandino G**, Avantaggiati ML and Chung FL. Reactivation of mutant p53 by a dietary-related compound, phenethyl isothiocyanate inhibits tumor growth. Cell Death Differ. 2016 Oct;23(10):1615-27.

156) Cordani M, Oppici E, Dando I, Butturini E, Pozza E, Nadal-Serrano M, Oliver J Roca P, Mariotto S, Cellini B, **Blandino G**, Palmieri M, Di Agostino S, Donadelli M. Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Mol Oncol. 2016 Aug;10(7):1008-29.

157) Cioce M., Strano S., Muti P., **Blandino G**. Mir 145/143: tumor suppressor, oncogenic microenvironmental factor … or both? Aging (Albany NY). 2016 May;8(5):1153-5.

158) Catena V., Bruno T., De Nicola F., Goeman F., Pallocca M., Iezzo S., Sorino C., Cigliana G., Floridi A., **Blandino G.**, and Fanciulli M. Deptor transcriptionally regulates Endoplasmic Reticulum homeostasis in Multiple Mieloma cells. Oncotarget. 2016 Oct 25;7(43):70546-70558.

159) Pass H., Lavilla C., Canino C., Goparaja C., Noreen S., **Blandino G.**, and Cioce M. Inhibition of the Colony-Stimulating-Factor 1 Receptor affects the resistance of lung cancer cells to cisplatin. Oncotarget. 2016 Aug 30;7(35):56408-56421.

160) Gentileschi MP., Lattanzi C., Menicagli F., Vincenzi B., Cigliana G., Baldi A., **Blandino G.**, Muti P., Fanciulli M., Spugnini E. Dietary protective effects against hepatocellular carcinoma development in Mdr2$^{-/-}$ knock-out mice. In Vivo. 2016 Jul-Aug;30(4):445-50.

161) Editorial: Haupt Y., and **Blandino G**. Human tumor-derived p53 mutants: a growing family of oncoproteins. Front Oncol. 2016 Jul 12;6:170.

162) Mao Y., Chen X., Fujita K., Motoki K., Sasabe T., Homma H., Tagawa K., Tamura T., Kaye J., Finkbeiner S., **Blandino G.**, Sudol S., and Okazawa H. Targeting TEAD/YAP-transcription-dependent necrosis TRIAD, ameloriates Hungtingon's disease pathology. Hum Mol Genet. 2016 Sep 12. pii: ddw303. [Epub ahead of print]

Publications 2017

163) Lo Sardo F, Forcato M, Capaci V., Sacconi A, Di Agostino S, Zanconato F, Del Sal G., Strano S, Bicciato S, and **Blandino G**. MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer Carcinogenesis. 2017 Jan;38(1):64-75. doi: 10.1093/carcin/bgw110. Epub 2016 Oct 17.

164) Milella M., Falcone I., Conciatori F., Matteoni S., Sacconi A., De Luca T., Bazzichetto C., Corbo V., Simbolo M., Sperduti I., Benfanti A., Del Curatolo A., Cesta Incani U., Malusa F., Eramo A., Sette G., Scarpa A., Konopleva M.,

Andreeff M., McJubrey J., **Blandino G.**, Todaro M., Stassi G., De Maria R., Cognetti F., Del bufalo D., and Ciuffreda L. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Sci Rep. 2017 Feb 21;7:43013. doi: 10.1038/srep43013

165) Bruno T, Valerio MC, Casadei L, De Nicola F, Goeman F, Pallocca M, Catena V, Iezzi S, Sorino C, De Santis A, Manetti C, **Blandino G,** Floridi A, and Fanciulli M. Che-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1 stabiliziation. J Exp Clin Cancer Res. 2017 Feb 18;36(1):32. doi: 10.1186/s13046-017-0497-1.

166) Canu V., Sacconi A., Lorenzon L., Biagioni F., Lo Sardo F., Muti P., Garofalo A., Strano S., D'Errico A., Grazi GL, Cioce M., and **Blandino G.** MiR-204 down-regulation elicited perturbation of a gene target signature common tu human cholangiocarcinoma and gastric cancer. Oncotarget. 2017 May 2;8(18):29540-29557. doi: 10.18632/oncotarget.15290.
PMID: 28199974

167) Raghu D., Paul P., Gulati T., Deb S., Khoo C., Russo A., Gallo E., **Blandino G.**, Chan AL., Takano E., Fox S., Williams S., Haupt S., Gamell C., Haupt Y. EA6P promotes prostate cancer by reducing p27 expression. Oncotarget. 2017 Jun 27;8(26):42939-42948. doi: 10.18632/oncotarget.17224.

168) Lorenzon L., Cippitelli C., Avantifiori R., Uccini S., French D., Torrisi MR., Ranieri D., Mercantini P., Canu V., **Blandino G.**, and Cavallini M. Down-regulated miRs specifically correlate with non-cardial gastric cancers and Lauren's classification system. J Surg Oncol. 2017 Aug;116(2):184-194. doi: 10.1002/jso.24648. Epub 2017 May 5.

169) Houde V., Donzelli S., Sacconi A., Galic S., Hammil JA., Bramson JL., Foster RA., Tsakidiris T., Kemp B., Grasso G., **Blandino G.**, Muti P., and Steinberg G. Genetic loss of AMPK B1 accelerates tumorigenesis in vivo. Mol Oncol. 2017 Sep;11(9):1143-1155. doi: 10.1002/1878-0261.12079. Epub 2017 Jun 28.

170) Bellissimo T., Ganci F., Gallo E., Sacconi A., Tito C., De Angelis L., Diso D., Anile M., Petrozza V., Giangaspero F., Pescarmona E., Facciolo F., Venuta F., Marino M., **Blandino G*.**, and Fazi F. Thymic epithelial tumors phenotype relies on miR-145-5p epigenetic regulation (*co-corresponding author). Mol Cancer. 2017 May 10;16(1):88. doi: 10.1186/s12943-017-0655-2.

171) Goeman F., Strano S., and **Blandino G.** MicroRNAs as key effectors in the p53 network. Int Rev Cell Mol Biol. 2017;333:51-90. doi: 10.1016/bs.ircmb.2017.04.003. Epub 2017 May 22.

172) Ferraioulo M, Verduci L., **Blandino G.** and Strano S. Mutant p53 and the Hippo transducers YAP and TAZ: a critical oncogenic node in human cancers. Int J Mol Sci. 2017 May 3;18(5). pii: E961. doi: 10.3390/ijms18050961. Review.

173) Ganci F., Sacconi A., Manciocco V., Covello R., Benevolo M., Rollo F., Spriano G., Strano S., Valsoni S., Bicciato S., Muti P., Fontemaggi G., and **Blandino G.** Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence. Mod Pathol. 2017 Oct;30(10):1387-1401. doi: 10.1038/modpathol.2017.62. Epub 2017 Jul 21.

174) Prusko M., Milano E., Forcato M., Donzelli S., Ganci F., Di Agostino S., Bates D., Bicciato S., Zylic M., Zylic A., **Blandino G*.**, Fontemaggi G. The mutant p53-ID4 complex controls VEGFA isoforms production by recruiting lncRNA MALAT1. (*co-corresponding author EMBO Rep. 2017 Aug;18(8):1331-1351. doi: 10.15252/embr.201643370. Epub 2017 Jun 26.

175) Rizzo A., Donzelli S., Girgenti V., Sacconi A., Vasco C., Salmaggi A.,

Blandino G., Maschio M., Ciusani E. In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells. J Exp Clin Cancer Res. 2017 Jun 6;36(1):76. doi: 10.1186/s13046-017-0546-9.

176) Pulito C., Mori F., Sacconi A., Goeman F., Fearaioulo M., Pasanisi P., Campagnoli C., Berrino F., Fanciulli M., Ford RJ., Ciuffreda L., Milella M., Steinberg G., Cioce M., Muti P., Strano S., and Blandino G. Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L anti-tumoral activities. Cell Discov. 2017 Jul 4;3:17022. doi: 10.1038/celldisc.2017.22. eCollection 2017.

177) Masciarelli S., Capuano E., Ottone T., Divona MD., De Panfilis S., Banella C., Noguera N., Picardi A., Fontemaggi G., Blandino G., Lo Coco F., and Fazi F. Retinoic acid and arsenic trioxide sensitize acute promyelocitic leukemia cells to ER-stress. Leukemia. 2017 Aug 4. doi: 10.1038/leu.2017.231. [Epub ahead of print]

178) Dinami R., Sestito R., Buemi V., Zappone A., Ciani Y., Mano M., Petti E., Sacconi A., Blandino G., Giacca M., Piazza S., Benetti R., Schoeftner S. Silencing of miR296 and miR-512 eunsures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells. Oncotarget. 2017 Sep 23;8(56):95674-95691. doi: 10.18632/oncotarget.21180. eCollection 2017 Nov 10.

179) Muti P., Donzelli S., Sacconi A., Hossain A., Frixa T., Ganci F., Sieri S., Krogh V., Berrino F., Biagioni F., Strano S., Beyene Y., Yarden Y., Blandino G. miRNA 513a-5p is an age-independent long-term predictor on breast cancer in premenopausal women. Carcinogenesis. 2017 Nov 4. doi: 10.1093/carcin/bgx126. [Epub ahead of print]

180) Verduci L, Ferraiuolo M., Sacconi A., Ganci F., Colombo T., Paci P., Strano S., Macino G., Rajesky N., and Blandino G. The oncogenic role of Circ-6 in Head and Neck Squamous Cell Carcinoma is mediated through mutantp53/YAP/TEAD complex. Genome Biol. 2017 Dec 20;18(1):237. doi: 10.1186/s13059-017-1368-y.

181) Lo Sardo F., Muti P., Blandino G and Strano S. Melatonin and Hippo pathway: is there existing cross-talk? Int J Mol Sci. 2017 Sep 6;18(9). pii: E1913. doi: 10.3390/ijms18091913.

182) Frixa T., Sacconi A., Cioce M., Roscilli G., Ferrara Fosca F., Aurisicchio L., Pulito C., Telera S., Carosi MA., Strano S., Donzelli S., and Blandino G. MicroRNA-128-mediated depletion of Drosha promotes lung cancer cell migration. Carcinogenesis. 2017 Dec 11. doi: 10.1093/carcin/bgx134. [Epub ahead of print]

Publications 2018

183) Di Martino S., Amoreo CA., Nuvoli B., Galati R., Strano S., Facciolo F., Pass H., Ciliberto G, Blandino G., De Maria R., Cioce M. HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. Oncogene. 2018 Jan 9. doi: 10.1038/s41388-017-0044-8. [Epub ahead of print].

184) Folgiero V., Sorino C., Pallocca M., De Nicola F., Goeman F, Bertaina V., Strocchio L., Romania P., Pitisci A., Iezzi S., Catena V., Bruno T., Strimpakos G., Passananti C., Mattei E., Blandino G., Locatelli F., and Fanciulli M. Che-1 is a new c-Myc target that sustains proliferation in pre-B-cell acute lymphoblastic leukemia. EMBO Rep. 2018 Jan 24. pii: e44871. doi: 10.15252/embr.201744871. [Epub ahead of print]

185) Di Modugno F., Caprara V., Chielli L., Tocci P., Spadaro F., Ferrandina G. Sacconi A., Blandino G., Nisticò P., Bagnato A., and Rosanò L. hMENA is a key regulator in endothelin-1/b-arrestin1-induced invadopodial function and metastatic process. PNAS, in press, 2018.

186) Di Agostino S., Valenti F., Sacconi A., Fontemaggi G., Pallocca M., Ganci F., Muti P., Strano S., and Blandino G. Aberrant activation of MIR205HG gene by mutant p53 protein elicits unrestrained proliferation in Head and Neck squamous cell carcinoma. Theranostic, in press, 2018.

187) Radovich M., et al. (Blandino G., in The Cancer Genome Atlas Research Network). The integrated genomic landscape of thymic epithelial tumors. Cancer Cell, in press, 2018.

188) Donzelli S., Milano E., Iosue I., Melucci E., Gallo E., Prusko M., Zylic A., Zylic M., Terrenato I., Mottolose M., Fazi F., Blandino G* and Fontemaggi G. Expression of ID4 protein in brest cancer cells determines reprogramming of tumor-associated macrophages. * co-corresponding author. Breast Cancer Research (submitted).

189) Tang GH, Saktunan M., Pond GR, Steinberg GR, Blandino G., Schunemann H., Muti P. Association of metformin with breast cancer incidence and mortality in patients with type 2 diabetes: a GRADE 2 assessed systematic review and meta-analysis. Can. Epi. Bio and Prev. (under second revision) 2018.

CHAPTERS IN BOOKS

1) Rizzo M.G, Soddu S, Crescenzi M, Blandino G, Scardigli R, Coen S, Sacchi A. Wild-type p53 overexpression diversely affects different leukemia cells. Proceedings of the XVI International Cancer Congress 1994. New Delhi (India), October 30-November 5. Monduzzi Editore, 1994.

2) Monti O, Damalas A, Strano S, and Blandino G. p73, p63 and mutant p53: members of protein complexes floating in cancer cells. Book for “25years of p53 research” by Kluwer Academic Publishers, 2005.

3) Blandino G.Gain of function p53. Encyclopedia of Cancer, 2nd edition by Springer Publisher, 2008.

4) Ganci F, Sacconi A, Manciocco V, Spriano G, Fontemaggi G, Blandino G. Molecular genetics and biology of head and neck squamous cell carcinoma: implications for diagnosis, prognosis and treatment. Head and Neck Cancer (ISBN 979-953-307-914-0), 2012.

5) Blandino G and Fontemaggi G. Id4 (Inhibitor of DNA binding). Encyclopedia of Signaling Molecules. Springer, 2012.

6) Goeman F, Fontemaggi G, Blandino G. ChIP-on-chip to identify mutant p53 targets. p53 Protocols: Second edition. Humana Press. Springer, 2012.

7) Donzelli S, Strano S, **Blandino G**. Yap and p73: a matter of mutual specificity in tumor suppression. The Hippo Signaling pathway and cancer. Springer, 2013.

8) Santoro R, Ferraiuolo M, **Blandino G**, Muti P, and Strano S. Melatonin Receptors and their Preventive Role in Carcinogenesis. Melatonin: Therapeutic Value and Neuroprotection. CRC Press.Chapter 18.Pages 223–232, 2014.

9) Santoro R, Strano S, **Blandino G**. Transcriptional Regulation by Mutant p53 and Oncogenesis. Mutant p53 and MDM2 in Cancer. Springer. Volume 85 of the series Subcellular Biochemistry pp 91-103, 2014.

10) Ganci F, Sacconi A, Manciocco V, Spriano G, Fontemaggi G, Carlini P and **Blandino G**. Radioresistance in Head and Neck Squamous Cell Carcinoma — Possible Molecular Markers for Local Recurrence and New Putative Therapeutic Strategies. Intech. Chapter 1. ISBN 978-953-51-2135-0, July 8,2015.

11) Mori F, Canu V, Lorenzon L, Garofalo A, **Blandino G**, Strano S. Cancer Gastric Chemoprevention: Isolation of Gastric Tumor-Initiating Cells. Methods Mol Biol. 1379:129-37, 2016.

12) Ganci F, **Blandino G**. microRNAs in Cancer Chemoprevention: Method to Isolate Them from Fresh Tissues. Methods Mol Biol. 1379:21-9, 2016.

13) Donzelli S, **Blandino G**, Muti P. Use of Buffy Coat miRNA Profiling for Breast Cancer Prediction in Healthy Women. Methods Mol Biol. 1379:13-9, 2016.

14) Ferraiuolo M, Strano S and **Blandino G**. Growth factors mediated cell signalling in Hippo pathway. Encyclopedia of Cell Biology, Volume 3, Pages 99-106, 2016.

LETTERS (PEER-REVIEWED)

1) Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, **Blandino G**.Metformin, diet and breast cancer: An avenue for chemoprevention, Cell Cycle. 8:16, 1-1; 15 August, 2009.

INVITED PRESENTATIONS

National and International Meetings (selected)

1) Speaker: The Mutp53 Consortium Kick-Off Meeting, Lillehammer, Norway, 2004.

2) Speaker: First IEO-IFOM Cancer Meeting, Milan, Italy, 2004.

3) Speaker: 26th Meeting of the European Study Group for Cell Proliferation (ESGCP), Prague, Czechoslovakia 2004.

4) Speaker: OECI 25th Annual Meeting, Berlin, Germany 2004.

5) Speaker: The Active p53 Consortium Kick-Off Meeting, Ghent, Belgium 2004.

6) Speaker: Life Sciences FP6 European Research Proposals Meeting, Poland 2005.

7) Speaker: P53 Marathon, Ein Gedi, Israel, 2005.

8) Speaker: 2nd IFOM –IEO Cancer Meeting, Milan, Italy 2006.

9) Speaker: International p53 Workshop, New York, USA 2006.

10) Speaker: P53 Marathon, Frascati, Italy 2006.

11) Speaker: XIV Telethon Scientific Convention, Salsomaggiore, Italy 2007.

12) Speaker: 3rd International p73/p63 Workshop, Rome, Italy 2007.

13) Speaker: World Stress Conference, August 25th. Title: "p53 family in apoptosis". Budapest, Hungary 2007..

14) Speaker: FEBS Workshop: The Biology of Modular Protein Domains, September 11th. Title: "The WW domain of YAP is critical in the execution of p73-mediated apoptosis in response to DNA damage". Seefeld, Austria 2007.

15) Speaker: Cancer Therapeutics: The Road Ahead, October 8th. Title: "Mutant p53 Gain of Function: SIMPs-mediated Disruption of the Protein Complex mutp53/p73 Enhances Selectively the Chemosensitivity of Mutant p53 Tumor Cells". Capri, Italy 2007.

16) Speaker: P53 Marathon. Deregulating the p53 Network : Origin and Consequences of TP53 mutations, November 14th. Title: "Mutant p53: an oncogenic transcription factor". Lyon, France 2007.

17) Speaker: Era of Hope Department of Defense Breast Cancer Research Program Meeting, June. Baltimore, USA 2008.

18) Speaker. Title: "The Potential of Metformin Use in Breast Cancer", Turin, Italy, 2009.

19) Speaker: P53 Marathon, March 27th. Title: "Mutant p53 triggers an oncogenic autoregulatory feedback loop". Acre, Israel 2009.

20) Speaker: University of Oxford, November 16th. Title:"Oncogenic cross-talks in human cancers". Oxford, England, 2009.

21) Speaker: 3rd International p63/73 Workshop, March 21st. Title: "Reactivation of p73 is dangerous for tumour cells". Rome, Italy, 2009.

22) Chair & Speaker:The HIPPO Tumor Suppressor Pathway: Brainstorming Workshop, April 22nd. Title: "YAP bridges p73 and PML pro-apoptic pathways". Rome, Italy, 2009.

23) Chair & Speaker: The 2nd Workshop on the HIPPO Tumour Suppressor Pathway, November 3rd. Title:"Role of YAP in apoptosis and senescence as tumour suppression mechanisms". Rome, Italy, 2010.

24) Speaker: Karolinska Institutet. Title: "Oncogenic cross-talks in human cancers". Stockolm, Sweden, 2010.

25) Speaker: SIBBM seminar: Frontiers in Molecular Biology, University of Padua, June 4th. Title: "Molecular determinants in breast cancer". Padova, Italy, 2010.

26) Speaker: University of Trieste, School of Molecular Biomedicine, March 30th. Title:
"Exploring tumour chemoresistance: miRNAs and cancer stem cells. Trieste, Italy, 2011.

27) Speaker: Institute SanRaffaele in Milan, Department of Experimental Onocology.
Title: "Exploring tumor chemoresistance: miRNAs and cancer stem cells". Milano, Italy, 2011.

28) Speaker: 5th Mutant p53 Workshop: "From bench to bedside across mouse models, May 23rd. Title: "Oncogenic transcriptional activity of mutant p53". Rome, Italy, 2011.

29) Chair: Mutant p53 activities in vivo: 5th Mutant p53 Workshop: "From bench to bedside across mouse models", 24th May. Rome, Italy, 2011.

30) Speaker:53rd Annual Meeting of the Italian Cancer Society: "Back to the future", Translating cancer research from bedside to bench and back, October 22nd. Title: "The Hippo-YAP pathway in organ size control tumorigenesis". Torino, Italy, 2011.

31) Translational Round Table, McMaster University, June 15. Title: "miRNA profiling: a way to dissect cancer alterations". Hamilton, Canada, 2012.

32) Departmental Seminar at McMaster University, June 19. Title: "Mutant p53 proteins: between loss and gain of function". Hamilton, Canada, 2012.

33) Special Guest seminar at Juravinsky Cancer Center, June 28, Title: "p53 mutations and miRNAs: a growing affair". Hamilton Canada, 2012.

34) Keynote Speaker: Retreat Meeting of the Biochemistry Department of the University of Alberta, May. Title:" Mutant p53 proteins: Between Loss and Gain of Function". Edmonton, Canada, 2013.

35) Chair: Hippo network in organ size control. The Hippo Tumor Suppressor Network: From Organ Size Control to Stem Cells and Cancer (E2-2013), May 19-23. Monterey, California, USA, 2013.

36) Speaker: The Hippo Tumor Suppressor Network: From Organ Size Control to Stem Cells and Cancer (E2-2013), May 19-23rd. Title: "Crosstalk between p53 Family and YAP in DNA damage and Senescence". Monterey, California, USA, 2013.

37) Chair: 6th International Mutant p53 workshop. June, 15-18. Toronto, Canada, 2013.

38) Speaker: 6th International Mutant p53 workshop.June, 15-18. Title: "Mutant

p53 and miRNAs: a growing affaire in tumorigenesis". Toronto, Canada, 2013.

39) Special Guest Seminar at the Weizmann Institute of Science, December 12. Title: "miRNAs: non-coding pleiotropic factors in cancer". Rehovot, Israel, 2013.

40) Invited Speaker at the Cancer Colloquium Univ. of St. Andrews, February 18-21. Title: "The protein complex YAP/PML in apoptosis and senescence". St. Andrews, Scotland, UK, 2014.

41) Invited Speaker at the 16thp53 Workshop Karolinska Institutet, June 15-19, Title: "The p53 and the Hippo Tumor Suppressor pathways: a growing cross-talk". Stockolm, Sweden, 2014.

42) Invited Speakers at Workshop "HIPPO in Cancer" April 15, Title: The YAP/PML protein complex cross-talks with p53 family members in apoptosis and senescence". Roma, Italy, 2014.

43) Invited Speaker at the University of Trieste, School of Molecular Biomedicine, April 4. Title: "Loss of tumor suppressor miRNAs activities in human cancers". Trieste, Italy, 2014.

.

44) Invited Speaker at the McMaster University Department of Medicine, February 5. Title: "microRNAs: Pleiotropic Small non-coding factor in cancer therapy". Hamilton, Canada, 2015.

45) Invited Speaker at the EPIGEN Meeting, April 24. Title: Study of mutant p53-dependent epigenetic modifications in head and neck tumors. Roma, Italy, 2015.

46) Invited Speaker at Bayer Workshop in Berlin, September 5. Title: Mutant p53 and YAP: an oncogenic transcriptional network in human cancers. Berlin, Germany, 2015.

47) Invited Speaker at the Department of Chemistry and Biochemistry, University of Windsor, Canada. Title: MicroRNAs: pleiotropic small non-coding factors in cancer therapy" April,18, 2016.

48) Invited Speaker at the 4th Annual Emphasis Symposium on" Cancer and Metabolism: Mechanisms and Outcomes" McMaster Univ, Canada. Title: MicroRNAs: short non-conding mediators of metformin anticancer effects. April 21, 2016.

49) Invited Speaker at the 7th International Mutant p53 Workshop, Melbourne, Australia. Title: Mutant p53 surfs into non-coding RNA networks. October 26-28, 2016.

50) Invited Speaker at the 29th AICC workshop on"Mutant p53 surfs into Non-Coding RNAs Network" L'Aquila, November 23-25, 2016.

51) Invited Speaker at the SIMEeP Winter School on "Liquid Biopsy-Circulating Cell Free DNA" Rome, November 30, 2016

52) Invited Speaker at IBPM-CNR "From basic research to technology transfer" Title: Mutant p53 protein: an oncogene regulator of coding and non-coding RNA network in human cancers". Rome, May 3, 2017.

53) Invited Speaker at the Weizmann Institute of Science "Mini-symposium on Cancer and Genome" Title: Mutant p53 protein: an oncogne regulator of coding and non-coding RNA network in human cancers". Rehovot, May 15, 2017.

54) Invited Speaker at the Weizmann Institute of Science “From Statistical Mechanical to Cancer Genomics”. Title: Tumor suppressor microRNAs in human breast cancer. Rehovot, May 17, 2017.

55) Invited Speaker at A* STAR Institute. Title: YAP and TAZ are critical transducers of gain of function mutant p53 proteins in human cancers. Singapore, July 7, 2017.

56) Invited Speaker at 17th p53 Workshop. Title: Aberrant crosstalk between the HIPPO and tumor suppressor pathways elicits unrestrained cell proliferation. Singapore, July 10, 2017.

In compliance with the Italian Legislative Decree no. 196 dated 30/06/2003, I hereby authorize the recipient of this document to use and process my personal details for the purpose of recruiting and selecting staff and I confirm to be informed of my rights in accordance to art. 7 of the above mentioned decree.

Rome, January 27, 2017 Giovanni Blandino